Patents Assigned to CellCentric Limited
  • Pharmaceutical compounds
    Patent number: 11377443
    Abstract: A compound which is an arylimidazolyl isoxazole of formula (I): (Formula (I)) or a pharmaceutically acceptable salt thereof. The compound has activity in modulating the activity of p300 and/or CBP and is used to treat cancer, particularly prostate cancer.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: July 5, 2022
    Assignee: CELLCENTRIC LIMITED
    Inventors: Neil Anthony Pegg, Stuart Thomas Onions, David Michel Adrien Taddei, Jonathan Shannon, Silvia Paoletta, Richard James Brown, Don Smyth, Gareth Harbottle
  • Pharmaceutical compounds
    Patent number: 10696666
    Abstract: A compound which is an arylimidazolyl isoxazole of formula (I): (Formula (I)) or a pharmaceutically acceptable salt thereof. The compound has activity in modulating the activity of p300 and/or CBP and is used to treat cancer, particularly prostate cancer.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: June 30, 2020
    Assignee: CELLCENTRIC LIMITED
    Inventors: Neil Anthony Pegg, Stuart Thomas Onions, David Michel Adrien Taddei, Jonathan Shannon, Silvia Paoletta, Richard James Brown, Don Smyth, Gareth Harbottle
  • Molecules and methods for demethylation of methylated nucleic acid sequences
    Patent number: 8658393
    Abstract: Demethylation of a methylated DNA sequence in a eukaryotic cell is described, utilizing a molecule that includes at least a first domain that exhibits a cytidine deaminase activity and at least a second domain that confers either a specific or non-specific DNA binding activity. The molecules of the invention are useful in somatic cell nuclear transfer and also in cancer therapy.
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: February 25, 2014
    Assignee: CellCentric Limited
    Inventors: Wolf Reik, Hugh Morgan, Chun-Fung Chan
  • MOLECULES AND METHODS FOR DEMETHYLATION OF METHYLATED NUCLEIC ACID SEQUENCES
    Publication number: 20130034881
    Abstract: Demethylation of a methylated DNA sequence in a eukaryotic cell is described, utilising a molecule that includes at least a first domain that exhibits a cytidine deaminase activity and at least a second domain that confers either a specific or non-specific DNA binding activity.
    Type: Application
    Filed: October 5, 2012
    Publication date: February 7, 2013
    Applicant: CELLCENTRIC LIMITED
    Inventor: CELLCENTRIC LIMITED
  • Compositions and method for epigenetic modification of nucleic acid sequences in vivo
    Patent number: 8298529
    Abstract: Demethylation of a methylated DNA sequence in a eukaryotic cell is described, utilizing a molecule that includes at least a first domain that exhibits a cytidine deaminase activity and at least a second domain that confers either a specific or non-specific DNA binding activity. The molecules of the invention are useful in somatic cell nuclear transfer and also in cancer therapy.
    Type: Grant
    Filed: April 10, 2007
    Date of Patent: October 30, 2012
    Assignee: CellCentric Limited
    Inventors: Wolf Reik, Hugh Morgan, Chun-Fung Chan
  • Compositions and Method for Epigenetic Modification of Nucleic Acid Sequences in Vivo
    Publication number: 20110138491
    Abstract: Demethylation of a methylated DNA sequence in a eukaryotic cell is described, utilising a molecule that includes at least a first domain that exhibits a cytidine deaminase activity and at least a second domain that confers either a specific or non-specific DNA binding activity. The molecules of the invention are useful in somatic cell nuclear transfer and also in cancer therapy.
    Type: Application
    Filed: April 10, 2007
    Publication date: June 9, 2011
    Applicant: CellCentric Limited
    Inventors: Wolf Reik, Hugh Morgan, Chun-Fung Chan